

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## NICE GENERAL PRACTICE INDICATOR DEVELOPMENT PROGRAMME

### Resource impact statement: NM147

**Date:** August 2017

#### **Indicators**

NM147: The percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: a) Assessment of stroke/VTE risk; b) Assessment of bleeding risk; c) Assessment of renal function, creatinine clearance, FBC and LFTs; d) Any adverse events related to anticoagulation; e) Assessment of compliance; f) Choice of anticoagulant.<sup>1</sup>

#### **Introduction**

Atrial fibrillation (AF) is a condition of the heart causing it to beat rapidly and irregularly. People with AF are at increased risk of blood clots and stroke. The risk of these complications can be minimised through appropriate use of anticoagulation therapy.

This statement covers a new indicator that is part of the NICE menu of indicators for general practice, following the recommendations of the NICE indicator advisory committee in June 2017.

This statement considers the likely resource impact of the proposed indicator in terms of the number of extra reviews and blood tests carried out.

---

<sup>1</sup> VTE: venous thromboembolism, FBC: full blood count, LFT: liver function test  
NICE indicator GP resource impact statement: NM147 (August 2017)

## Resource impact

There are around 54.8 million people in England ([Office for National Statistics, 2016](#)). The latest data available ([NHS Digital, 2016](#)) indicate that the diagnosed prevalence of AF is 1.71%, equivalent to around 937,000 people in England and that of these people, nearly 78% (730,000) are currently treated with an anticoagulant.

Pilot data (University of Birmingham and York Health Economics Consortium) showed that of people currently treated with an anticoagulant, around 29% have had a review of their anticoagulant therapy in the previous 12 months.

Assuming that achieving the indicator will need a GP appointment lasting 17 minutes ([PSSRU, 2016](#)), 5 minutes of practice nurse time ([PSSRU, 2016](#)) to take blood samples for testing and 3 blood tests ([Reference costs 2015-16 Department of Health, 2016](#)), the total unit cost per person is £63.60. Costs will differ when healthcare professionals other than GPs carry out the review needed to achieve the indicator.

Table 1 shows estimated cost at achievement levels of 40% to 80%.

**Table 1 Estimated annual cost of implementing indicator NM147**

	Proportion	Population	Unit cost (£)	Total (£)
England population		54,786,327		
Prevalence of diagnosed AF (all ages)	1.71%	936,846		
Proportion treated with an anticoagulant	78%	729,709		
<b>Current practice</b>				
Proportion that have annual review of anticoagulant therapy	29%	213,667	63.60	13,589,200
<b>Total cost of current practice</b>				<b>13,589,200</b>
<b>Future practice at 40%</b>				
Achievement of indicator	40%	291,884	63.60	18,563,800
<b>Total cost of future practice</b>				<b>18,563,800</b>
<b>Resource impact at 40% (cost of future practice less cost of current practice)</b>				<b>4,974,600</b>
<b>Future practice at 80%</b>				
Achievement of indicator	80%	583,768	63.60	37,127,600
<b>Total cost of future practice</b>				<b>37,127,600</b>
<b>Resource impact at 80% (cost of future practice less cost of current practice)</b>				<b>23,538,400</b>

The annual resource impact of implementing indicator NM147, compared to a baseline achievement of 29.3%, is estimated to be approximately £5.0 million at 40% achievement and approximately £23.5 million at 80% achievement.

This does not include any savings which may be made as a result of reduced adverse events associated with AF such as stroke and blood clots.